(Q37085889)

18 August 2017

1 reference

title

Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer (English)

1 reference

18 August 2017

1 reference

Robert G Uzzo

1

1 reference

18 August 2017

Naomi B Haas

series ordinal

2

1 reference

18 August 2017

Paul L Crispen

series ordinal

3

1 reference

18 August 2017

Vladimir M Kolenko

series ordinal

4

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

18 August 2017

12

1 reference

inferred from page(s)

published in

Cancer

1 reference

18 August 2017

112

1 reference

18 August 2017

8

1 reference

18 August 2017

1660-1671

1 reference

An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.

18 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Death receptors in chemotherapy and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Apoptotic pathways: ten minutes to dead

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Cell surface Death Receptor signaling in normal and cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

TRAIL and apoptosis induction by TNF-family death receptors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

The inhibitors of apoptosis (IAPs) and their emerging role in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

BID: a novel BH3 domain-only death agonist

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Suppression of TNF-alpha-induced apoptosis by NF-kappaB

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Differential expression of TRAIL and its receptors in benign and malignant prostate tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: implication for attenuated p53 response to apoptotic stresses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kappaB sites in prostatic carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Diallyl trisulfide suppresses growth of PC-3 human prostate cancer xenograft in vivo in association with Bax and Bak induction.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Allium vegetables and risk of prostate cancer: a population-based study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Inhibitors of NF-kappaB signaling: 785 and counting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

D,L-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

The Bcl-2 apoptotic switch in cancer development and therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Bcl-2 family proteins as targets for anticancer drug design

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

IAP family proteins--suppressors of apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Inhibition of death receptor signals by cellular FLIP

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Bid, a BH3-only multi-functional molecule, is at the cross road of life and death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Induction of apoptosis by the Bcl-2 homologue Bak

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Human ICE/CED-3 protease nomenclature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Caspases: the proteases of the apoptotic pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

PUMA, a novel proapoptotic gene, is induced by p53

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Inhibitory effect of snake venom toxin from Vipera lebetina turanica on hormone-refractory human prostate cancer cell growth: induction of apoptosis through inactivation of nuclear factor kappaB.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Diallyl trisulfide, a constituent of processed garlic, inactivates Akt to trigger mitochondrial translocation of BAD and caspase-mediated apoptosis in human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Induction of Fas clustering and apoptosis by coral prostanoid in human hormone-resistant prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Mahanine inhibits growth and induces apoptosis in prostate cancer cells through the deactivation of Akt and activation of caspases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3sigma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23318

7 January 2021

Identifiers

DOI

10.1002/CNCR.23318

1 reference

18 August 2017

1 reference